The Animal protocol used in this study was approved by Institutional Animal Care & Use Committee (IACUC) at Thomas Jefferson University. C57BL/6J cyclin D1fl/fl mice were a kind gift from Dr. Piotr Sicinski (Dana-Farber Cancer Institute, Boston, MA). C57BL/6J Rosa26-CreERT2 mice which express the Tamoxifen-inducible CreERT2 fusion protein were from Dr. Thomas Ludwig (Columbia University, New York, NY). Cyclin D1fl/fl -Rosa26CreERT2/CreERT2 mice were generated by crossing cyclin D1fl/fl mice with Rose26-Cre-ERT2 mice. Cyclin D1 knock-out mice were generated with Cyclin D1fl/fl-Rosa26CreERT2/CreERT2 mice by intra-peritoneal injection of Tamoxifen (1 mg/200 μl Sunflower seed oil) for 5 days. Cyclin D1wt/wt-Rosa26CreERT2/CreERT2 mice were used as control. Mammary glands from these mice were collected four weeks after IP injection of Tamoxifen. Immunohistochemistry staining was conducted on paraffin embedded mammary gland sections. The primary antibodies used were mouse monoclonal anti-cyclin D1 (clone DCS-6) (sc-20044) (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal anti-G9a (clone C6H3) (Cell Signaling Technology, Inc, Danvers, MA), and mouse monoclonal anti-H3K9me2 (ab1220) (Abcam Inc.).
Anti g9a clone c6h3
Manufactured by Cell Signaling Technology
Anti-G9a (clone C6H3) is a monoclonal antibody that recognizes the G9a protein, which is a histone methyltransferase that catalyzes the mono- and di-methylation of histone H3 at lysine 9 (H3K9). This antibody can be used for various applications, such as Western blotting and immunoprecipitation, to study the expression and function of the G9a protein.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using anti g9a clone c6h3
1
Cyclin D1 Knockout Mouse Model
2
Cyclin D1 Knockout Mice for Mammary Gland Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The Animal protocol used in this study was approved by the Institutional Animal Care & Use Committee at Thomas Jefferson University. C57BL/6J cyclin D1fl/fl mice were a kind gift from Dr. Piotr Sicinski (Dana-Farber Cancer Institute, Boston, MA). C57BL/6J Rosa26-CreERT2 mice, which express the tamoxifen-inducible CreERT2 fusion protein were from Dr. Thomas Ludwig (Columbia University, New York, NY). Cyclin D1fl/fl-Rosa26CreERT2/CreERT2 mice were generated by crossing cyclin D1fl/fl mice with Rose26-Cre-ERT2 mice. Cyclin D1 knockout mice were generated with Cyclin D1fl/fl-Rosa26CreERT2/CreERT2 mice by intraperitoneal injection of tamoxifen (1 mg/200 µl sunflower seed oil) for 5 days. Cyclin D1wt/wt-Rosa26CreERT2/CreERT2 mice were used as control. Mammary glands from these mice were collected 4 weeks after IP injection of tamoxifen. Immunohistochemistry staining was conducted on paraffin-embedded mammary gland sections. The primary antibodies used were mouse monoclonal anti-cyclin D1 (clone DCS-6) (sc-20044) (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal anti-G9a (clone C6H3) (Cell Signaling Technology, Inc, Danvers, MA), and mouse monoclonal anti-H3K9me2 (ab1220) (Abcam Inc.).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!